2025-09-11 - Analysis Report
Okay, here's a report analyzing Hims & Hers Health (HIMS), incorporating all the data you've provided.

**Report: Hims & Hers Health Inc (HIMS) Analysis**

**Company Overview:** Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, offering personalized treatments and medications.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (HIMS):** 169.34%
*   **Cumulative Return (VOO):** 39.61%
*   **Absolute Divergence (Current):** 105.4
*   **Relative Divergence:** 51.0 (This indicates that HIMS's current divergence from VOO is positioned in the middle range of its historical divergence spectrum.)

    *The significant outperformance relative to the S&P 500 suggests strong growth or market favor during the analyzed period. However, the relative divergence of 51.0 indicates that HIMS's outperformance is not at its peak historically, implying potential for further upside or increased volatility.*

**Alpha, Beta Analysis:**

| Year       | CAGR      | MDD   | Alpha    | Beta  | Cap(B) |
|------------|-----------|-------|----------|-------|--------|
| 2019-2021  | -46.0%    | 51.0% | -47.0%   | 0.1   | 1.5    |
| 2020-2022  | -15.0%    | 72.1% | -4.0%    | 0.1   | 1.4    |
| 2021-2023  | -51.0%    | 72.1% | -61.0%   | 0.0   | 2.0    |
| 2022-2024  | 127.0%    | 78.4% | 97.0%    | -0.0  | 5.5    |
| 2023-2025  | 164.0%    | 80.7% | 119.0%   | -0.0  | 10.8   |

*Analysis: The table reveals a volatile performance history.  The most recent periods (2022-2025) demonstrate substantial growth (CAGR) and strong alpha generation, indicating outperformance relative to the market.  The negative beta suggests a slight inverse correlation to the market (though very small).*

**2. Recent Stock Price Movement**

*   **Current Price:** $47.79
*   **Last Market Data:** Price: $47.78, Previous Close: $47.79, Change: -$0.02 (Relatively small price change)
*   **5-Day Moving Average:** $47.68
*   **20-Day Moving Average:** $45.54
*   **60-Day Moving Average:** $50.57

*Analysis: The current price is slightly above the 5-day and 20-day moving averages, suggesting a short-term upward trend. However, it's below the 60-day moving average, which might indicate some resistance at higher levels. The small price change in the last market doesn't indicate any immediate significant volatility.*

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.3261 (Low Risk)
*   **RSI:** 64.16 (Approaching overbought territory, but not yet decisively so)
*   **PPO:** 1.65 (Positive, indicating a short-term upward trend)
*   **Hybrid Signal:** Cash_0%_Buy 90% of cash (11 shares - Safe - MRI:0.33) (Suggests a buy signal based on the model)
*   **Recent (20-day) Relative Divergence Change:** 1.6 (+) (Indicates recent short-term increase in the divergence between HIMS and the benchmark)
*   **Expected Return (%):** -11.6% (This suggests that the model predicts underperformance relative to the S&P 500 over the long term based on current data).

*Analysis: The MRI indicates a low-risk environment for the stock. The RSI is moderately high, suggesting the stock might be approaching overbought conditions. The PPO confirms a recent upward trend. The expected return is negative, implying potential future underperformance compared to the S&P 500.*

**4. Recent News & Significant Events (Yahoo Finance)**

*   **Testosterone Product Launch:** Hims & Hers is expanding into the low testosterone market with new products, including an FDA-approved oral testosterone therapy (KYZATREX®) through a collaboration with Marius Pharmaceuticals.
*   **Analyst/Market Reaction:**  News headlines suggest a positive market reaction to the testosterone product launch, with the stock jumping.
*   **Regulatory Scrutiny:**  The mention of Trump tasking the FDA to crack down on misleading drug advertising could be a relevant factor, potentially affecting how Hims & Hers markets its products.

*Analysis: The recent news is overwhelmingly positive, driven by the expansion into the men's health market, specifically testosterone treatments.  This appears to be a catalyst for the recent stock price increase.*

**4-2. Analyst Opinions:**

*   **Consensus:** Hold (Mean: 2.75)
*   **Target Price:** Average: $49.45 / High: $85.00 / Low: $28.00

*Analysis:  The analyst consensus is currently "Hold". The average target price suggests a slight upside from the current price, while the high target price indicates significant potential upside according to some analysts.*

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-08-04 | 0.19 | 0.54 B$    |
| 2025-05-05 | 0.22 | 0.59 B$    |
| 2024-11-04 | 0.35 | 0.40 B$    |
| 2024-08-05 | 0.06 | 0.32 B$    |
| 2025-08-04 | 0.06 | 0.32 B$    |

*Analysis:  The EPS and revenue figures show positive trends. The two most recent quarters exhibit stronger EPS figures, indicating improved profitability. Revenue also generally shows an upward trend.*

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $0.54B    | 76.39%        |
| 2025-03-31   | $0.59B    | 73.50%        |
| 2024-12-31   | $0.48B    | 76.81%        |
| 2024-09-30   | $0.40B    | 79.16%        |
| 2024-06-30   | $0.32B    | 81.30%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE    |
|--------------|-----------|--------|
| 2025-06-30   | $0.56B    | 7.55%  |
| 2025-03-31   | $0.55B    | 9.01%  |
| 2024-12-31   | $0.48B    | 5.46%  |
| 2024-09-30   | $0.44B    | 17.18% |
| 2024-06-30   | $0.36B    | 3.67%  |

*Analysis: The data reveals a positive trend in revenue over the observed period, which is generally a good sign. Profit margins have been consistently high, indicating efficient cost management. However, there has been a slight decrease in profit margin in recent quarters. Equity has also increased, reflecting growth in the company's net assets. ROE has fluctuated but remains at reasonable levels, suggesting that the company is generating profits from its equity.*

**7. 종합적인 분석 (Overall Analysis)**

Hims & Hers Health (HIMS) has demonstrated significant outperformance compared to the S&P 500 over the analyzed period. Recent positive news, particularly the launch of testosterone products, appears to be driving the stock price higher. Financial performance shows increasing revenue and strong profit margins, which are favorable indicators.

However, several factors warrant consideration:

*   **Analyst Consensus:** The "Hold" rating suggests analysts are taking a wait-and-see approach.
*   **Long-Term Expected Return:** The negative expected return indicates that the current valuation may be high relative to future growth prospects or that the model anticipates future underperformance compared to the S&P 500.
*   **RSI:** The RSI is approaching overbought levels, which could signal a potential pullback.
*   **Regulatory Risk:** Potential increased scrutiny from the FDA regarding drug advertising is a factor to monitor.

**Conclusion:**

HIMS presents a mixed picture. The recent positive momentum driven by new product launches and strong revenue growth is encouraging. However, investors should be mindful of the analyst consensus, potentially overbought conditions, and the negative long-term expected return. Careful monitoring of financial performance, regulatory developments, and market sentiment is recommended.
